|Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: A phase II trial|
|Li, Jin-luan; Ji, Jia-fu2; Cai, Yong1; Li, Xiao-fan; Li, Yong-heng; Wu, Hao; Xu, Bo; Dou, Fang-yuan3; Li, Zi-yu2; Bu, Zhao-de2; Wu, Ai-wen2; Tham, Ivan W. K.4|
|关键词||Intensity-modulated radiotherapy Capecitabine Rectal cancer|
|刊名||RADIOTHERAPY AND ONCOLOGY|
|WOS标题词||Science & Technology|
|类目[WOS]||Oncology ; Radiology, Nuclear Medicine & Medical Imaging|
|研究领域[WOS]||Oncology ; Radiology, Nuclear Medicine & Medical Imaging|
|关键词[WOS]||TOTAL MESORECTAL EXCISION ; RADIATION-THERAPY ; SMALL-BOWEL ; CHEMORADIOTHERAPY ; SURVIVAL ; VOLUME ; RADIOCHEMOTHERAPY ; LYMPHADENECTOMY ; CHEMOTHERAPY ; NETHERLANDS|
Purpose: We aimed to assess the safety and efficacy of preoperative intensity-modulated radiotherapy (IMRT) with oral capecitabine in patients with locally advanced mid-low rectal cancer using a concomitant boost technique.
Materials and methods: Patients with resectable locally advanced mid-low rectal cancer (node-negative >= T3 or any node-positive tumor) were eligible. The eligible patients received IMRT to 2 dose levels simultaneously (50.6 and 41.8 Gy in 22 fractions) with concurrent capecitabine 825 mg/m(2) twice daily 5 days/week. The primary end point included toxicity, postoperative complication, and pathological complete response rate (ypCR). The secondary endpoints included local recurrence rate, progression-free survival (PFS), and overall survival (OS).
Results: Sixty-three eligible patients were enrolled; five patients did not undergo surgery. Of the 58 patients evaluable for pathologic response, the ypCR rate was 31.0%(95% CI 19.1-42.9). Grade 3 toxicities included diarrhea (9.5%), radiation dermatitis (3.2%), and neutropenia (1.6%). There was no Grade 4 toxicity reported. Four (6.9%) patients developed postoperative complications. Two-year local recurrence rate, PFS, and OS were 5.7%, 90.5%, and 96.0%, respectively.
Conclusions: The design of preoperative concurrent boost IMRT with oral capecitabine could achieve high rate of ypCR with an acceptable toxicity profile. (C) 2011 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 102 (2012) 4-9
|作者单位||1.Peking Univ, Dept Radiat Oncol, Sch Oncol, Canc Hosp,Beijing Canc Hosp & Inst, Beijing 100142, Peoples R China|
2.Beijing Canc Hosp & Inst, Dept Surg Gastroenterol, Beijing, Peoples R China
3.Natl Univ Canc Inst, Dept Radiat Oncol, Singapore, Singapore
4.Beijing Canc Hosp & Inst, Dept Pathol, Beijing, Peoples R China
|Li, Jin-luan,Ji, Jia-fu,Cai, Yong,et al. Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: A phase II trial[J]. RADIOTHERAPY AND ONCOLOGY,2012,102(1):4-9.|
|APA||Li, Jin-luan.,Ji, Jia-fu.,Cai, Yong.,Li, Xiao-fan.,Li, Yong-heng.,...&Tham, Ivan W. K..(2012).Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: A phase II trial.RADIOTHERAPY AND ONCOLOGY,102(1),4-9.|
|MLA||Li, Jin-luan,et al."Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: A phase II trial".RADIOTHERAPY AND ONCOLOGY 102.1(2012):4-9.|